Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pfizer's Phase 3 Study Of Torisel In Combination With Bevacizumab Fails

RELATED NEWS
Trade PFE now with 

Pfizer Inc (PFE: Quote) Friday announced that its Phase 3 INTORACT trial , evaluating the combination of bevacizumab plus TORISEL compared with bevacizumab plus interferon-alfa-2a, or IFN-a-2a, did not meet its primary endpoint of superiority in extending progression free survival , or PFS, in the study population.

The company stated that the Phase 3 trial was carried out in the first-line treatment of patients with advanced renal cell carcinoma, or RCC, across risk groups.

The company further stated that the combination of bevacizumab and IFN-a-2a is approved as first-line treatment for advanced RCC and clinical supplies of both of these drugs in this trial were provided through an agreement with Roche.

"This trial advances our knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "Additional analyses will be performed to help us understand this result. The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."

Register
To receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Germany's unemployment increased unexpectedly in August as worsening economic activity weighed on job creation. In addition, consumer price inflation, at a four-and-a-half-year low, boosted the scope for more stimulus from the European Central Bank. The number of people out of work increased by a seasonally adjusted 2,000 persons to 2.901 million in August, the Federal Labor Agency reported. NASA has approved the development of the world's most powerful rocket, designed to take humans beyond Earth orbit and to Mars. NASA officials Wednesday announced they have completed a rigorous review of the Space Launch System (SLS) -- the heavy-lift, exploration class rocket under development - and approved the program's progression from formulation to development, something no other exploration Eurozone economic confidence weakened more-than-expected in August to its lowest level in eight months, underscoring rising pessimism amid heightened geopolitical tensions and stagnating economic recovery. The economic confidence index fell to 100.6 in August, the lowest score since December, from 102.1 in July, the European Commission said Thursday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.